Posted in M&A / Deals Immutrin raises $87M to advance drug for progressive heart disease March 24, 2026 BioPharma Dive The fresh funding will help the biotech startup advance a candidate to treat a genetic disorder, ATTR-CM, that has become a battleground for companies like Pfizer, Alnylam and BridgeBio. M&A / DealsCardiovascularRead full story